SGLT2 inhibitor dapagliflozin enhances skeletal muscle fatty acid uptake in subjects with type 2 diabetes: a positron emission tomography study

被引：0
|
作者：
Latva-Rasku, A. [1 ]
Tuisku, J. [1 ]
Bhowmik, A. [1 ]
Keskinen, H. [1 ]
Rebelos, E. [1 ]
Laurila, S. [1 ]
Koffert, J. [1 ]
Nummenmaa, L. [1 ]
Heurling, K. [2 ]
Oscarsson, J. [3 ]
Turku, P. Nuutila [1 ]
机构：
[1] Univ Turku, Turku PET Ctr, Turku, Finland
[2] Antaros Med, Molndal, Sweden
[3] AstraZeneca AB, Molndal, Sweden
来源：
DIABETOLOGIA | 2023年 / 66卷 / SUPPL 1期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
133
引用
收藏
页码：S72 / S72
页数：1
相关论文
共 50 条
  • [1] SGLT2 Inhibitor Dapagliflozin Increases Skeletal Muscle and Brain Fatty Acid Uptake in Individuals With Type 2 Diabetes: A Randomized Double-Blind Placebo-Controlled Positron Emission Tomography Study
    Latva-Rasku, Aino
    Rebelos, Eleni
    Tuisku, Jouni
    Aarnio, Richard
    Bhowmik, Achol
    Keskinen, Helmi
    Laurila, Sanna
    Lahesmaa-Hatting, Minna
    Pekkarinen, Laura
    Isackson, Henrik
    Kirjavainen, Anna K.
    Koffert, Jukka
    Heurling, Kerstin
    Nummenmaa, Lauri
    Ferrannini, Ele
    Oldgren, Jonas
    Oscarsson, Jan
    Nuutila, Pirjo
    DIABETES CARE, 2024, 47 (09)
  • [2] Effect of SGLT2 inhibitor dapagliflozin on skeletal muscle fatty acid metabolism in patients with type 2 diabetes
    Gemmink, A.
    op den Kamp, Y. J. M.
    de Ligt, M.
    Dautzenberg, B.
    Esterline, R.
    Hoeks, J.
    Schrauwen-Hinderling, V. B.
    Kersten, S.
    Havekes, B.
    Koves, T. R.
    Muio, D. M.
    Hesselink, M. K. C.
    Oscarsson, J.
    Phielix, E.
    Schrauwen, P.
    DIABETOLOGIA, 2022, 65 (SUPPL 1) : S5 - S5
  • [3] Effects of SGLT2 inhibitor dapagliflozin in patients with type 2 diabetes on skeletal muscle cellular metabolism
    op den Kamp, Yvo J. M.
    Gemmink, Anne
    de Ligt, Marlies
    Dautzenberg, Bas
    Kornips, Esther
    Jorgensen, Johanna A.
    Schaart, Gert
    Esterline, Russell
    Pava, Diego A.
    Hoeks, Joris
    Schrauwen-Hinderling, Vera B.
    Kersten, Sander
    Havekes, Bas
    Koves, Timothy R.
    Muoio, Deborah M.
    Hesselink, Matthijs K. C.
    Oscarsson, Jan
    Phielix, Esther
    Schrauwen, Patrick
    MOLECULAR METABOLISM, 2022, 66
  • [4] DAPAGLIFLOZIN, AN SGLT2 INHIBITOR FOR THE TREATMENT OF TYPE 2 DIABETES
    Demaris, K. M.
    White, J. R.
    DRUGS OF TODAY, 2013, 49 (05) : 289 - 301
  • [5] Dapagliflozin, an SGLT2 inhibitor, for diabetes
    Hanefeld, Markolf
    Forst, Thomas
    LANCET, 2010, 375 (9733): : 2196 - 2198
  • [6] The SGLT2 Inhibitor Dapagliflozin Increases the Oxidation of Ingested Fatty Acids to Ketones in Type 2 Diabetes
    Herring, Roselle A.
    Shojaee-Moradie, Fariba
    Stevenage, Mary
    Parsons, Iain
    Jackson, Nicola
    Mendis, Jeewaka
    Middleton, Benita
    Umpleby, A. Margot
    Fielding, Barbara A.
    Davies, Melanie
    Russell-Jones, David L.
    DIABETES CARE, 2022, 45 (06) : 1408 - 1415
  • [7] Dapagliflozin, an SGLT2 Inhibitor, Reduces Plasma Levels of Uric Acid in Patients with Type 2 Diabetes
    Hardy, Elise
    Rohwedder, Katja
    Hruba, Veronika
    Salsali, Afshin
    Ying, Lisa
    Sugg, Jennifer E.
    List, James F.
    Parikh, Shamik J.
    DIABETES, 2011, 60 : A286 - A286
  • [8] Better response to the SGLT2 inhibitor dapagliflozin in young adults with type 2 diabetes
    Nakamura, Yuta
    Nagai, Yoshio
    Terashima, Yuko
    Nishine, Ami
    Ishii, Satoshi
    Kato, Hiroyuki
    Ohta, Akio
    Tanaka, Yasushi
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (17) : 2553 - 2559
  • [9] Safety and efficacy of the SGLT2 inhibitor dapagliflozin in older patients with type 2 diabetes
    Fioretto, P.
    de Bruin, T. W.
    Johnsson, E.
    Ptaszynska, A.
    Parikh, S.
    List, J. F.
    DIABETOLOGIA, 2013, 56 : S383 - S383
  • [10] RENOPROTECTIVE EFFECT OF SGLT2 INHIBITOR DAPAGLIFLOZIN IN TYPE-1 DIABETES
    Balogh, Dora
    Hodrea, Judit
    Lenart, Lilla
    Hosszu, Adam
    Szkibinszkij, Edgar
    Vannay, Adam
    Wagner, Laszlo
    Szabo, Attila
    Fekete, Andrea
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2017, 32
12345